Downloads: 1
[3cdecf]:
/
all_studies.csv
| # | Study Title - Link to Page here | Study ID | Study Start Date | APC Date | Cancer Site | Trial Type | Trial Phase | Tumor Type | Modalities | Area Offered | Trial Status | Total Included | Median Age | Mean Age | Min Age | Max Age | # Female | # Male | # White | #Hispanic (ethnicity) | # Non White | # Asian | #American Indian | #Native Hawaiian or Pacifi Islande | #Black | #Not Reported/Other | full text link | notes | contact library? | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Paclitaxel, Carboplatin and Radiotherapy as Induction Therapy in Locally Advanced Head and Neck Cancer | NCT00176254 | May-00 | Oct-12 | head and neck | Primary | 2 | SCC | Radiation + Drug | United States | C | 40 | 54 | 36 | 81 | 8 | 32 | Y | |||||||||||||||
| 2 | Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | NCT00639769 | Feb-02 | May-07 | oral cavity, oropharynx, hypopharynx, larynx, nasopharynx, nasal septum | Recurrent/Metastatic | 2 | SCC | Drug | United States | C | 40 | 58 | 7 | 33 | https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.23545 | N | ||||||||||||||||
| 3 | EVALUATION OF AMIFOSTINE FOR MUCOSAL AND HEMOPOETIC PROTECTION AND CARBOPLATIN, TAXOL, RADIOTHERAPY IN THE MANAGEMENT OF PATIENTS WITH HEAD AND NECK CANCER.(GCC 0202) | NCT00270790 | May-02 | Dec-05 | head and neck | Primary/Recurrent | 2 | SCC | Drug + Device | United States | C | 21 | 58.2 | 48 | 70 | 3 | 18 | cant find | Y | ||||||||||||||
| 4 | Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Head and Neck Cancer | NCT00047008 | Jul-02 | Jun-10 | oral cavity, oropharynx, hypopharynx, larynx | Primary/Recurrent | 3 | SCC | Radiation + Drug | United States | C | 721 | 56 | 26 | 82 | 124 | 597 | 589 | 132 | https://pubmed.ncbi.nlm.nih.gov/20530316/ | N | ||||||||||||
| 5 | Radiosensitization With Celecoxib and Chemoradiation for Head and Neck Cancer (RAD0201) | NCT00581971 | Sep-02 | Dec-07 | oral cavity, oropharynx, hypopharynx, larynx | Primary/Recurrent | 1,2 | SCC | Radiation + Drug | United States | C | 30 | 53.83 | 4 | 26 | https://ascopubs.org/doi/abs/10.1200/jco.2006.24.18_suppl.5582 | N | ||||||||||||||||
| 6 | High-Dose Radiation Therapy Plus Chemotherapy in Treating Patients With Advanced Nose or Throat Cancer | NCT00052429 | Sep-02 | Nov-10 | nasopharynx | Primary | 1,2 | not specifed | Procedure + Radiation + Drug | United States | C | 25 | 8 | 17 | 8 | 17 | 11 | 6 | https://www.sciencedirect.com/science/article/pii/S0360301610001252?via%3Dihub | N | |||||||||||||
| 7 | A Study of a New Combination and Schedule of Chemotherapy Drugs for the Treatment of Head and Neck Cancer | NCT00148122 | Nov-02 | Aug-08 | head and neck | Recurrent/Metastatic | 2 | SCC, adenocarcinoma | Drug | United States | C | 38 | 59.5 | 39.9 | 75.1 | 6 | 32 | 36 | 0 | 2 | 0 | 0 | 2 | cant find | N | ||||||||
| 8 | Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Adv | NCT01185171 | Jan-03 | Jul-18 | nasopharynx | Primary | 2 | SCC,poorly differentiated carcinoma, lymphoepithelioma | Drug | United States | C | 69 | 55 | 49 | 64 | 14 | 55 | 58 | 1 | 11 | 0 | 0 | 0 | 10 | 0 | N | |||||||
| 9 | Radiation Therapy With or Without Chemotherapy in Reducing Mouth Dryness in Patients With Nasopharyngeal Cancer | NCT00057785 | Feb-03 | Feb-07 | nasopharynx | Palliative | 2 | SCC | Radiation + Drug | United States | C | 68 | 48.5 | 17 | 51 | 37 | 31 | 23 | 0 | 1 | 5 | 2 | https://ascopubs.org/doi/10.1200/JCO.2008.19.9109 | N | |||||||||
| 10 | Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy | NCT00095836 | Mar-03 | Mar-11 | thyroid | Primary/Recurrent/Metastatic | 2 | thyroid | Drug | United States | C | 27 | 64.5 | 11 | 16 | race not collected | N | ||||||||||||||||
| 11 | Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia | NCT00099021 | Jun-03 | Jun-08 | precancerous | precancerous | 2 | precancerous | Drug | United States | C | 21 | 56.1 | 27 | 75 | 12 | 9 | cant find | precancerous? | Y | |||||||||||||
| 12 | Photodynamic Therapy With Porfimer Sodium in Treating Patients With Precancerous Lesions, Cancer, or Other Disease of the Aerodigestive Tract | NCT00453336 | Jun-03 | Aug-09 | oral cavity, oropharynx, larynx | Primary | 2 | SCC or carcnoma in situ | Drug + Procedure | United States | C | 45 | 66 | 30 | 92 | 23 | 22 | 45 | https://jnccn.org/view/journals/jnccn/10/Suppl_2/article-pS-65.xml?ArticleBodyColorStyles=inline%20pdf | N | |||||||||||||
| 13 | Cox-2 Inhibition in Radiation-induced Oral Mucositis | NCT00698204 | Jul-03 | Sep-12 | head and neck | Palliative | 2 | not specifed | Drug | United States | C | 40 | 54.58 | 34 | 71 | 8 | 32 | 39 | 2 | 1 | 0 | 0 | 0 | 1 | 0 | N | |||||||
| 14 | Salivary Gland Surgery Before Radiation Therapy in Preventing Radiation-Caused Xerostomia in Patients With Head and Neck Cancer | NCT00068237 | Aug-03 | Jan-08 | oropharynx, hypopharynx, larynx, unknown primary | Palliative | 2 | SCC | Procedure + Radiation | United States + Canada | C | 44 | 56.5 | 42 | 74 | 8 | 36 | https://www.sciencedirect.com/science/article/pii/S0360301612003008?via%3Dihub | N | ||||||||||||||
| 15 | Optimized Intensity Modulated Irradiation for Head and Neck Cancer | NCT00580983 | 8/1/03 | Jun-10 | oropharynx | Primary | NA | non-specific | Radiation + Drug | United States | C | 73 | 55 | 50 | 78 | 8 | 65 | here | Y | ||||||||||||||
| 16 | Zalutumumab in Head and Neck Cancer | NCT00093041 | Dec-03 | Jan-05 | oral cavity, oropharynx, hypopharynx, larynx, nasopharynx, paranasal sinus | Recurrent/Metastatic | 1,2 | SCC | Drug | Europe | C | 28 | 57 | 47 | 79 | 6 | 22 | https://www.thegreenjournal.com/article/S0167-8140(07)00247-2/fulltext | cant access | Y | |||||||||||||
| 17 | Ph II Study Examining Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation &/or Chemotherapy | NCT00258310 | Dec-03 | Feb-11 | oral cavity, oropharynx, hypopharynx, larynx, nasopharynx | Primary/Recurrent/Metastatic | 2 | SCC | Drug + Procedure | United States | C | 35 | 58 | 43 | 74 | 7 | 28 | Y | |||||||||||||||
| 18 | Fruit and Vegetable Extracts in Treating Patients With Stage I-IV, Stage IVA/IVB Head and Neck Cancer | NCT00064298 | Jan-04 | Oct-08 | oral cavity, oropharynx, hypopharynx, larynx | Primary/Recurrent/Metastatic (cured) | 2 | SCC | Dietary Supplement | United States | C | 134 | 58.5 | 30 | 82 | 21 | 113 | 111 | 9 | 23 | 0 | 11 | 3 | https://journals.sagepub.com/doi/10.1177/1534735416684947 | N | ||||||||
| 19 | Adjuvant Cetuximab and Chemoradiotherapy Using Either Cisplatin or Docetaxel in Treating Patients With Resected Stage III or Stage IV Squamous Cell Carcinoma or Lymphoepithelioma of the Head and Neck | NCT00084318 | Apr-04 | Mar-09 | oral cavity, oropharynx, hypopharynx, larynx | Primary/Recurrent | 2 | SCC | Biological + Drug+ Radiation | United States | C | 203 | 56 | 21 | 80 | 52 | 151 | https://ascopubs.org/doi/full/10.1200/JCO.2013.53.9163?role=tab | N | ||||||||||||||
| 20 | Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial) | NCT00095875 | Aug-04 | Apr-12 | oral cavity, oropharynx, hypopharynx, larynx | Primary | 3 | SCC | Drug | United States + Europe | C | 145 | 54.5 | 35 | 74 | 18 | 127 | 127 | 18 | https://www.sciencedirect.com/science/article/pii/S1470204513700111?via%3Dihub | N | ||||||||||||
| 21 | Study of D-Methadone in Patients With Chronic Pain | NCT00588640 | Oct-04 | Jul-08 | head and neck + others | Palliative | 1,2 | not specifed | Drug | United States | C | 10 | 6 | 4 | https://wmpllc.org/ojs/index.php/jom/article/view/259 | N | |||||||||||||||||
| 22 | IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma | NCT00229723 | Nov-04 | Jun-08 | head and neck, not nasopharynx, oral cavity, larynx | Primary | 2 | SCC | Drug + Radiation | United States + Europe + Asia | C | 226 | 53.2 | 21 | 74 | 28 | 198 | 210 | 16 | 0 | https://www.sciencedirect.com/science/article/pii/S0167814011003847?via%3Dihub | caucasian included indian here | N | ||||||||||
| 23 | Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE) (DeCIDE) | NCT00117572 | Nov-04 | Dec-16 | not specified, not lip | Primary | 3 | SCC or poorly differentiated | Drug + Procedure | United States + Europe | C | 273 | 56.8 | 31 | 82 | 42 | 231 | 229 | 44 | 39 | 5 | https://ascopubs.org/doi/figure/10.1200/JCO.2013.54.6309 | N | ||||||||||
| 24 | Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME) | NCT00122460 | Dec-04 | Mar-07 | not specified, not nasopharynx or salivary | Recurrent/Metastatic | 3 | SCC | Drug | Europe + Russia | C | 442 | 56.9 | 43 | 399 | 432 | 10 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639534/ | N | ||||||||||||||
| 25 | Phase II Study of Concurrent C225, Cisplatin and Radiation in Stage IV Squamous Cell Carcinoma of the Head and Neck | NCT00096174 | Dec-04 | Jul-09 | not specified, not nasopharynx or salivary | Primary/Recurrent | 2 | SCC or poorly differentiated | Biological + Drug+ Radiation | United States | C | 60 | 54.8 | 42 | 78.5 | 9 | 51 | https://ascopubs.org/doi/10.1200/jco.2008.26.15_suppl.6006 | N | ||||||||||||||
| 26 | Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer | NCT00089297 | Dec-04 | Feb-10 | oral cavity, oropharynx, hypopharynx, larynx | Primary | 2 | SCC | Biological + Drug+ Radiation | United States | C | 63 | 57 | 31 | 76 | 14 | 49 | 56 | 7 | 0 | 0 | 7 | 0 | https://www.sciencedirect.com/science/article/pii/S0923753419366037?via%3Dihub | N | ||||||||
| 27 | Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442) | NCT00343083 | Dec-04 | Jun-11 | oral cavity, oropharynx, hypopharynx, larynx, nasopharynx, paranasal sinus | Primary | 2 | SCC | Radiation + Drug | United States | C | 43 | 58 | 42 | 75 | 6 | 37 | 33 | 10 | 10 | 0 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4447113/ | N | ||||||||||
| 28 | S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer | NCT00100789 | Jan-05 | Feb-08 | head and neck | Recurrent/Metastatic | 2 | SCC | Drug | United States | C | 63 | 63.1 | 40.7 | 82.9 | 13 | 50 | 56 | 7 | 0 | 11 | 2 | N | ||||||||||
| 29 | Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer | NCT00248560 | Jan-05 | Dec-09 | head and neck | Recurrent/Metastatic | 2 | SCC | Drug | United States | C | 36 | 60 | 60.2 | 46 | 79 | 10 | 26 | 22 | 0 | 14 | 0 | 12 | 2 | https://www.hindawi.com/journals/isrn/2012/159568/ | N | |||||||
| 30 | SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | NCT00095628 | Jan-05 | Jul-10 | not specified, not nasopharynx | Recurrent/Metastatic | 2 | SCC | Drug + Other | Canada | C | 20 | 60 | 41 | 75 | 3 | 17 | 20 | https://link.springer.com/article/10.1007/s10637-007-9098-8/tables/1 | N | |||||||||||||
| 31 | Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck | NCT00519077 | Mar-05 | May-08 | head and neck | recurrent/metastatic | 2 | SCC | Drug | United States | C | 44 | 9 | 35 | https://www.sciencedirect.com/science/article/pii/S136883751200108X?via%3Dihub | N | |||||||||||||||||
| 32 | Phase II (Treatment) Study of Oxaliplatin and Capecitabine in Advanced Head and Neck Malignancies | NCT00266279 | Apr-05 | Oct-09 | head and neck | Recurrent/Metastatic | 2 | SCC | Drug | United States | C | 15 | 5 | 10 | 15 | http://ocrss.louisville.edu/clients/hscro/conspectus/search | N | ||||||||||||||||
| 33 | Real-Time Internet Evaluation of Swallowing | NCT00580138 | May-05 | Mar-09 | head and neck | not specified | NA | not specifed | observational | United States | C | 30 | 62 | 13 | 17 | Y | |||||||||||||||||
| 34 | Study of ABT-510 (Thrombospondin Analogue) in Patients with Advanced Head and Neck Cancer | NCT00113334 | Jun-05 | Mar-08 | head and neck | Palliative | 1b/2 | SCC | Drug | United States | C | 6 | 59 | 43 | 64 | 2 | 4 | cant find | Y | ||||||||||||||
| 35 | GM-CSF Mouthwash for Preventing and Treating Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer | NCT00293462 | Jun-05 | Dec-09 | head and neck | Palliative | 3 | not specifed | Biological + Other | United States | C | 91 | 54.5 | 24 | 67 | 56 | 4 | 35 | 21 | 0 | 2 | 6 | 6 | N | |||||||||
| 36 | Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer | NCT00509665 | Jun-05 | May-11 | oropharynx, larynx, hypopharynx, oral cavity | Recurrent/Metastatic | 2 | SCC | Drug | United States | C | 18 | 56.5 | 45 | 77 | https://aacrjournals.org/clincancerres/article/17/18/6097/76548/Results-of-a-Phase-II-Trial-of-Gemcitabine-Plus | N | ||||||||||||||||
| 37 | A Study of Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy and Concurrent Chemotherapy | NCT00626639 | Jul-05 | May-07 | oral cavity, oropharynx, hypopharynx, larynx, nasopharynx | Palliative | 1,2 | SCC | Radiation + Drug | Europe | C | 5 | 52 | 38 | 68 | 0 | 5 | 5 | 0 | 0 | 0 | 0 | 0 | N | |||||||||
| 38 | A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer | NCT00210470 | Jul-05 | Dec-10 | oral cavity, oropharynx, hypopharynx, larynx | Primary | 2 | SCC | Biological + Drug | United States + Mexico | C | 27 | 57.4 | 7 | 20 | Y | |||||||||||||||||
| 39 | Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer | NCT00101582 | Aug-05 | Sep-07 | oral cavity, oropharynx, hypopharynx, larynx, nasopharynx | Palliative | 3 | SCC | Radiation + Drug | United States | C | 188 | 55.5 | 29 | 159 | 173 | 5 | 15 | 0 | 1 | 0 | 9 | 0 | N | |||||||||
| 40 | Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer | NCT00140556 | Aug-05 | May-09 | oral cavity, oropharynx, hypopharynx, supraglottic, glottic larynx | Primary | 1 | SCC | Radiation + Drug | United States | C | 28 | 57 | 6 | 22 | https://aapm.onlinelibrary.wiley.com/doi/full/10.1118/1.3427487 | N | ||||||||||||||||
| 41 | Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | NCT00425750 | Aug-05 | Jun-09 | oral cavity, oropharynx, hypopharynx, larynx | Recurrent/Metastatic | 2 | SCC | Drug + Other | United States | C | 25 | 55 | 7 | 18 | 22 | 0 | 3 | 0 | 2 | 1 | https://www.sciencedirect.com/science/article/pii/S0923753419389409?via%3Dihub | N | ||||||||||
| 42 | Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer | NCT00281840 | Sep-05 | Apr-12 | oral cavity, oropharynx, hypopharynx, larynx | Primary | 2 | SCC | Biological+ Drug + Procedure + Radiation | United States | C | 30 | 55 | 43 | 73 | 4 | 26 | https://onlinelibrary.wiley.com/doi/10.1002/hed.23813 | N | ||||||||||||||
| 43 | Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer | NCT00226239 | Oct-05 | Jul-13 | nasopharynx, hypopharynx, base of tongue | Primary | 2 | SCC | Drug + Procedure | United States | C | 39 | 55 | 21 | 74 | 5 | 34 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3018361/ | N | ||||||||||||||
| 44 | Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer | NCT00265941 | Nov-05 | Jan-11 | oropharynx, hypopharynx, larynx | Primary | 3 | SCC | Radiation + Drug | United States | C | 891 | 57 | 31 | 79 | 105 | 786 | 810 | 72 | https://ascopubs.org/doi/10.1200/JCO.2013.53.5633 | N | ||||||||||||
| 45 | Study of Pemetrexed and Bevacizumab in Patients With Head and Neck Cancer | NCT00222729 | Nov-05 | Oct-13 | not specified, not nasopharynx | Recurrent/Metastatic | 2 | SCC | Drug | United States | C | 40 | 59 | 36 | 85 | 8 | 32 | https://ascopubs.org/doi/10.1200/JCO.2010.33.3591 | N | ||||||||||||||
| 46 | The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer | NCT00243347 | Dec-05 | May-08 | head and neck + lung | Recurrent/Metastatic | 1 | not specifed + NSCLC | Drug | United States + Europe | C | 19 | 58.1 | 4 | 15 | 19 | https://ascopubs.org/doi/abs/10.1200/jco.2009.27.15_suppl.6023 | N | |||||||||||||||
| 47 | Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms | NCT00666926 | Dec-05 | Apr-09 | head and neck + others | not specified | 1 | not specifed | Drug | North America + Australia | C | 99 | 58.7 | 43 | 56 | 84 | 15 | 6 | 6 | 3 | https://ascopubs.org/doi/figure/10.1200/JCO.2011.38.9346 | N | |||||||||||
| 48 | Pemetrexed Chemotherapy in Poor-Risk Patients with Advanced Head and Neck Cancer | NCT00293579 | Feb-06 | May-08 | oral cavity, oropharynx, hypopharynx, larynx | Recurrent/Metastatic | 3 | SCC | Drug | United States | C | 795 | 57.8 | 21 | 84 | 56 | 342 | 476 | 27 | 318 | 142 | 29 | 0 | https://pubmed.ncbi.nlm.nih.gov/22434360/ | N | ||||||||
| 49 | A Study Of Lapatinib Versus Placebo Followed By Chemoradiation In Patients With Locally Advanced Head And Neck Cancer | NCT00371566 | Mar-06 | Dec-07 | oral cavity, oropharynx, hypopharyx, larynx | Primary | 2 | SCC | Drug | Europe + Asia | C | 107 | 57.1 | 20 | 87 | 60 | 47 | 33 | 14 | 0 | 0 | N | |||||||||||
| 50 | Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA) | NCT00304278 | Mar-06 | May-15 | oral cavity, oropharynx, hypopharynx, larynx | Primary | 2 | SCC | Radiation + Drug | United States | C | 21 | 52 | 2 | 19 | 17 | 0 | https://link.springer.com/article/10.1007/s00280-013-2225-7/tables/1 | 4 unknown ethnicities | Y | |||||||||||||
| 51 | Cisplatin, Fluorouracil, Iressa, and Radiation Therapy Patients With Locally Advanced Head and Neck Cancer | NCT00352105 | Apr-06 | Sep-08 | head and neck | Primary | 1, 2 | SCC | Radiation + Drug | United States | C | 60 | 57 | 7 | 53 | 58 | 0 | 2 | 0 | 2 | 0 | cant find | N | ||||||||||
| 52 | Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer | NCT00301028 | Apr-06 | Sep-11 | oral cavity, oropharynx, hypopharynx, larynx, nasopharynx | Primary/Recurrent | 2 | SCC | Biological+ Drug + Procedure + Radiation | United States | C | 47 | 53 | 21 | 78 | 14 | 33 | 42 | 2 | 5 | 1 | 2 | 0 | https://ascopubs.org/doi/10.1200/JCO.2009.23.0425 | N | ||||||||
| 53 | S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer | NCT00337129 | May-06 | Aug-08 | not specified, not nasopharynx or salivary | Recurrent/Metastatic | 2 | SCC | Drug | United States | C | 40 | 61 | 44 | 87 | 11 | 29 | 33 | 0 | 7 | 1 | 5 | 1 | N | |||||||||
| 54 | Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer | NCT00410826 | Jun-06 | May-12 | oral cavity, oropharynx, hypopharynx, larynx, nasopharynx | Metastatic | 2 | SCC | Drug + Radiation + Procedure | United States | C | 203 | 56 | 35 | 77 | 28 | 175 | 165 | 21 | 37 | 4 | 1 | 0 | 30 | 3 | https://ascopubs.org/doi/10.1200/JCO.2012.46.3299 | N | ||||||
| 55 | Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer (EPIC) | NCT00468169 | Jul-06 | Aug-12 | unknown primary | Primary/Recurrent | 2 | SCC | Drug | United States | C | 110 | 55.8 | 32 | 81 | 17 | 93 | 83 | 0 | 27 | 0 | 22 | 5 | cant find | N | ||||||||
| 56 | Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients with Head and Neck Cancer | NCT00971867 | Aug-06 | Nov-08 | head and neck | Recurrent/Metastatic | 2 | not specified | Drug | Asia | C | 11 | 2 | 9 | cant find | Y | |||||||||||||||||
| 57 | Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer | NCT00387335 | Aug-06 | Mar-10 | head and neck | Recurrent/Metastatic | 2 | SCC | Drug | United States | C | 22 | 57 | 40 | 78 | 7 | 15 | 19 | 3 | 0 | 1 | 0 | 2 | 0 | https://link.springer.com/article/10.1007/s10637-009-9296-7/tables/1 | N | |||||||
| 58 | A Phase II Study of Pemetrexed Plus Gemcitabine for Metastatic/Recurrent Head and Neck Cancer | NCT00589667 | Sep-06 | Jul-10 | oral cavity, pharynx, larynx, paranasal sinus, or unknown primary | Recurrent/Metastatic | 2 | SCC | Drug | United States | C | 26 | 60 | 52.5 | 22 | 83 | 6 | 20 | https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.25464 | N | |||||||||||||
| 59 | A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer | NCT00409565 | Sep-06 | Feb-12 | head and neck | Recurrent/Metastatic | 2 | SCC | Drug | United States | C | 46 | 61.5 | 33 | 92 | 12 | 34 | 42 | 3 | 4 | 1 | 0 | 3 | N | |||||||||
| 60 | Cisplatin, Bevacizumab, and Intensity-Modulated Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer | NCT00423930 | Oct-06 | Jul-16 | head and neck | Primary | 2 | SCC | Biological+ Drug + Procedure + Radiation | United States | C | 44 | 54 | 27 | 75 | 8 | 36 | 41 | 3 | 3 | 0 | 2 | 1 | cant find | N | ||||||||
| 61 | Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer | NCT00387127 | Nov-06 | Jun-09 | oral cavity, oropharynx, hypopharynx, larynx | Primary | 2 | SCC | Drug | Worldwide | C | 67 | 56.1 | 7 | 60 | 50 | 17 | 12 | 4 | 1 | 0 | N | |||||||||||
| 62 | Zalutumumab in Patients With Non-curable Head and Neck Cancer | NCT00382031 | Nov-06 | Dec-09 | oral cavity, oropharynx, hypopharynx, larynx | Recurrent/Metastatic | 3 | SCC | Drug + Other | Europe + Brazil + Canada + Russia | C | 286 | 57.5 | 57 | 28 | 81 | 34 | 252 | https://www.sciencedirect.com/science/article/pii/S1470204511700341?via%3Dihub | N | |||||||||||||
| 63 | Treatment of Head & Neck Cancer With Chemotherapy and Radiation | NCT00392704 | Dec-06 | Aug-08 | head and neck | Primary | 2 | SCC | Radiation + Drug | United States | C | 60 | 56 | 39 | 76 | 10 | 50 | https://journals.lww.com/journalppo/Abstract/2011/09000/Combined_Modality_Treatment_With_Chemotherapy,.1.aspx | Y- cant access | ||||||||||||||
| 64 | Pemetrexed and Oxaliplatin in Treating Patients With Locally Advanced Head and Neck Cancer | NCT00503997 | Dec-06 | Jun-09 | not specified, not nasopharynx or salivary | Primary | 2 | SCC | Drug | United States | C | 42 | 56 | 7 | 35 | https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.26364 | N | ||||||||||||||||
| 65 | A Study for Patients With Head and Neck Cancer | NCT00415194 | Dec-06 | Mar-10 | not specified, not nasopharynx or salivary | Recurrent/Metastatic | 3 | not specified | Drug | worldwide | C | 795 | 57.62 | 109 | 686 | 476 | 27 | 319 | 262 | 29 | 1 | N | |||||||||||
| 66 | Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery | NCT00424255 | Dec-06 | Mar-13 | oral cavity, oropharynx, hypopharynx, larynx | Primary | 3 | SCC | drug + radiation + other | worldwide | C | 688 | 53.8 | 115 | 573 | 442 | 246 | 245 | 0 | 0 | 0 | 1 | N | ||||||||||
| 67 | Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer | NCT00485485 | Jan-07 | Mar-10 | head and neck | Primary | 2 | SCC | Drug | United States | C | 7 | 64 | 62 | 44 | 75 | 2 | 5 | 6 | 0 | 0 | 0 | 0 | 0 | 1 | https://www.jto.org/article/S1556-0864(15)31737-8/fulltext | N | ||||||
| 68 | PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response | NCT00454779 | Jan-07 | Jun-12 | not specified, not nasopharynx | Recurrent/Metastatic | 2 | SCC | Drug | United States + Europe | C | 113 | 58.6 | 14 | 99 | Y | |||||||||||||||||
| 69 | Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer | NCT00462735 | Feb-07 | Oct-10 | base of tongue/hypopharyngeal | Primary | 2 | SCC or poorly differentiated | Drug + Procedure | United States | C | 33 | 59 | 18 | 77 | 9 | 24 | 23 | 5 | 10 | 0 | 5 | 0 | https://clinicaltrials.gov/ct2/show/record/NCT00462735?recrs=e&rslt=With&cond=Head+and+Neck+Cancer&draw=3&rank=92 | N | ||||||||
| 70 | Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer | NCT00970502 | Feb-07 | Nov-10 | head and neck | Primary | 1,2 | SCC or poorly differentiated | Drug | United States | C | 14 | 64 | 43 | 93 | 3 | 11 | 10 | 2 | 0 | 0 | 0 | 2 | 2 | N | ||||||||
| 71 | Robotic Assisted Surgery in Upper Aerodigestive Tract Surgery | NCT00473564 | Feb-07 | Dec-13 | head and neck | not specified | NA | not specifed | Procedure | United States | C | 170 | 61.9 | 43 | 127 | 154 | 0 | 0 | 1 | 15 | 0 | https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/410085 | N | ||||||||||
| 72 | Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies | NCT00496860 | May-07 | Oct-09 | head and neck + others | Metastatic | 1 | not specifed | Biological | United States | C | 26 | 54 | 27 | 79 | 9 | 17 | 25 | 1 | 0 | 0 | 0 | 1 | 0 | N | ||||||||
| 73 | Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer (SPECTRUM) | NCT00460265 | May-07 | May-10 | not specified, not nasopharynx or salivary | Recurrent/Metastatic | 3 | SCC | Drug | North America + South America + Europe + Asia | C | 657 | 58.1 | 87 | 570 | 539 | 25 | 31 | 75 | 6 | 12 | https://www.sciencedirect.com/science/article/pii/S1470204513701815?via%3Dihub | N | ||||||||||
| 74 | Cetuximab in Treating Patients With Precancerous Lesions of the Upper Aerodigestive Tract | NCT00524017 | May-07 | Dec-11 | upper aerodigestive | not specified | 2 | precancerous | Biological | United States | C | 19 | 7 | 12 | 18 | 1 | 1 | 0 | https://pubmed.ncbi.nlm.nih.gov/26686755/ | N | |||||||||||||
| 75 | A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen | NCT00623831 | May-07 | May-12 | head and neck + others | metastatic | 1 | not specifed | Biological | Europe | C | 17 | 57.4 | 8 | 9 | 17 | 0 | 0 | 0 | 0 | 0 | 0 | N | ||||||||||
| 76 | Low-level Laser Therapy to Prevent Oral Mucositis in Head and Neck Patients | NCT01439724 | Jun-07 | Jun-08 | oropharynx, hypopharynx, nasopharynx | Palliative | 3 | SCC | Device | South America | C | 94 | 54.6 | 12 | 82 | 94 | https://www.sciencedirect.com/science/article/pii/S1368837515003668?via%3Dihub | repeated on .gov (explains 277 vs 278) | N | ||||||||||||||
| 77 | Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer | NCT00492089 | Jun-07 | Aug-10 | head and neck+ brain, meninges | Primary/Recurrent | 2 | not specifed | Drug + Procedure | United States | C | 14 | 48.7 | 6 | 8 | 14 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2908725/ | N | |||||||||||||||
| 78 | A Pilot Trial of Image-Guided Adaptive Radiotherapy for Head and Neck Cancer | NCT00490282 | Jun-07 | May-15 | oropharynx | Primary | NA | SCC | Radiation | United States | C | 25 | 54 | 38 | 75 | 2 | 23 | cant find | Y | ||||||||||||||
| 79 | Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | NCT00507767 | Jul-07 | Feb-10 | head and neck | Recurrent/Metastatic | 2 | SCC | Drug + Procedure | United States | C | 15 | 54 | 46 | 78 | 4 | 11 | 12 | 3 | 3 | 1 | 0 | 0 | 2 | 0 | N | |||||||
| 80 | Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | NCT00513435 | Jul-07 | Mar-11 | oral cavity, oropharynx, hypopharynx, larynx | Recurrent/Metastatic | 2 | SCC | Drug | United States | C | 9 | 53.8 | 2 | 7 | 9 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3705960/ | N | |||||||||||||||
| 81 | Dynasplint Therapy for Trismus in Head and Neck Cancer | NCT00507208 | Jul-07 | Jul-15 | head and neck | Palliative | NA | not specifed | Device + Other | United States | C | 53 | 15 | 38 | 40 | 1 | 13 | 12 | 0 | N | |||||||||||||
| 82 | Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck | NCT00725764 | Aug-07 | May-09 | head and neck | Recurrent/Metastatic | 2 | SCC | Drug | United States | C | 14 | 59.6 | 1 | 13 | 12 | 2 | 1 | 1 | N | |||||||||||||
| 83 | BIBW 2992 (Afatinib) in Head & Neck Cancer | NCT00514943 | Aug-07 | Mar-10 | head and neck | Recurrent/Metastatic | 2 | SCC | Drug | United States + Europe | C | 124 | 58.3 | 17 | 107 | 86 | 6 | 1 | 5 | 32 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4143093/ | N | |||||||||||
| 84 | PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer) | NCT00446446 | Oct-07 | Dec-10 | oral cavity, oropharynx, hypopharynx, larynx | Recurrent/Metastatic | 2 | SCC | Drug | United States + Australia | C | 52 | 59.8 | 16 | 36 | 48 | 4 | 3 | 1 | N | |||||||||||||
| 85 | Study of Addition of Panitumumab to Chemoradiation Therapy in Patients With Locally Advanced Head and Neck Cancer | NCT00500760 | Oct-07 | Mar-11 | oral cavity, oropharynx, hypopharynx, larynx | Primary/Recurrent | 2 | SCC | Radiation + Drug | United States + Europe + Canada + Asia | C | 153 | 57.4 | 20 | 133 | 137 | 3 | 16 | 12 | 2 | https://www.sciencedirect.com/science/article/pii/S1470204514711982?via%3Dihub | N | |||||||||||
| 86 | A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis | NCT00565721 | Nov-07 | Oct-11 | head and neck + others | primary/metastatic | 2 | not specified | Drug | United States | C | 25 | 50.4 | 16 | 9 | N | |||||||||||||||||
| 87 | Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck | NCT00547157 | Nov-07 | Dec-11 | oral cavity, oropharynx, hypopharynx, larynx | Metastatic | 2 | SCC | Drug | North America + Europe | C | 152 | 57.1 | 25 | 127 | 148 | 4 | 4 | 0 | 0 | 0 | https://www.sciencedirect.com/science/article/pii/S1470204514712008?via%3Dihub | N | ||||||||||
| 88 | Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer | NCT00661427 | Nov-07 | Aug-12 | head and neck | Recurrent/Metastatic | 2 | SCC | Biological | United States | C | 61 | 60 | 9 | 52 | 61 | https://jnccn.org/view/journals/jnccn/10/11/article-p1391.xml#T1 | N | |||||||||||||||
| 89 | Evaluating the Effectiveness of Escitalopram to Prevent Depression in Head and Neck Cancer Patients Receiving Treatment (PROTECT) | NCT00536172 | Dec-07 | Jun-12 | oral cavity, pharynx, skin, salivary gland, sinus | Palliative | 4 | SCC, salivary, skin | Drug | United States | C | 148 | 63 | 30 | 118 | 143 | 3 | 5 | 5 | https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/1699734 | N | ||||||||||||
| 90 | UAB 0718 - Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer (UAB0718) | NCT00570232 | Dec-07 | Dec-14 | oral cavity, oropharynx, hypopharynx, larynx | Recurrent | 2 | SCC | Drug | United States | C | 31 | 13 | 18 | cant find | Y | |||||||||||||||||
| 91 | Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer | NCT00798655 | Dec-07 | Jun-15 | oral cavity, oropharynx, hypopharynx, larynx | Primary | 2 | SCC | Radiation + Drug | United States | C | 44 | 58 | 23 | 81 | 8 | 36 | https://www.sciencedirect.com/science/article/pii/S0923753419365512?via%3Dihub | N | ||||||||||||||
| 92 | Zalutumumab in Non-curable Patients With SCCHN | NCT00542308 | Jan-08 | Aug-11 | oral cavity, oropharynx, hypopharynx, larynx | Palliative | 2 | SCC | Drug | United States + Europe + South America + Israel | C | 90 | 59.1 | 18 | 72 | 73 | 1 | 16 | https://link.springer.com/article/10.1007/s00280-014-2459-z | N | |||||||||||||
| 93 | Radiation Therapy Cisplatin With or Without Fluorouracil Patients With Stage III or Stage IV Head and Neck Cancer | NCT00608205 | Jan-08 | Sep-12 | oral cavity, oropharynx, hypopharynx, larynx | Primary/Recurrent | 3 | SCC | Radiation + Drug | United States | C | 69 | 9 | 60 | 68 | 0 | 1 | 0 | 1 | 0 | cant find | Y | |||||||||||
| 94 | Study of Sorafenib/Cetuximab in Head and Neck Cancer | NCT00815295 | Jan-08 | Jul-13 | head and neck | Recurrent/Metastatic | 1,2 | SCC | Drug | United States | C | 28 | 61 | 8 | 20 | Y | |||||||||||||||||
| 95 | etuximab and Combination Chemotherapy in Patients With Stage III-IV Resectable Oropharynx Cancer (ECHO-07) | NCT00665392 | Feb-08 | Jul-12 | oropharynx | Primary | 2 | SCC | Drug | Europe | C | 42 | 56.1 | 8 | 34 | https://onlinelibrary.wiley.com/doi/10.1002/cam4.408 | N | ||||||||||||||||
| 96 | Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck | NCT00617734 | Mar-08 | Feb-12 | oropharynx, hypopharynx, larynx | Recurrent/Metastatic | 2 | SCC | Biological | United States | C | 91 | 60 | 35 | 81 | 18 | 73 | 76 | 5 | 15 | 2 | 0 | 0 | 8 | 5 | N | |||||||
| 97 | Efficacy of Electrical Stimulation for Dysphagia in Head & Neck Cancer Patients | NCT00629265 | Mar-08 | Apr-12 | head and neck | Palliative | NA | not specifed | Device | United States | C | 168 | 61.9 | 24 | 144 | 121 | 13 | 34 | 14 | 19 | 1 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4833725/ | N | ||||||||||
| 98 | Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer | NCT00851877 | Mar-08 | Oct-13 | oropharynx, hypopharynx, larynx | Primary/Recurrent | 1,2 | SCC | Biological + Drug+ Radiation | United States | C | 34 | 55.5 | 45 | 76 | 13 | 21 | https://www.tandfonline.com/doi/abs/10.1080/07357907.2016.1213275?journalCode=icnv20 | Y- cant access | ||||||||||||||
| 99 | F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients | NCT00721799 | Mar-08 | Dec-14 | head and neck | Primary | 2 | SCC | Drug | United States | C | 26 | 57.8 | 2 | 24 | 23 | 0 | 0 | 0 | 0 | 3 | N | |||||||||||
| 100 | Using Traditional Acupuncture in the Management of Cancer Treatment Related Lymphoedema (AMWELL-SL) | NCT00828516 | Apr-08 | Sep-09 | head and neck + others | Palliative | NA | not specifed | Other | Europe | C | 35 | 57.5 | 30 | 5 | 35 | https://www.ejoncologynursing.com/article/S1462-3889(11)00105-0/fulltext | N |